melatonin has been researched along with Dermatitis, Atopic in 18 studies
Dermatitis, Atopic: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has pleiotropic properties such as suppressive effects on serum level of autotaxin which relieves itching of atopic dermatitis." | 5.48 | Is melatonin effective for pruritus caused by liver disease? ( Esmaeili, A; Namazi, S, 2018) |
| "Melatonin also has sleep-inducing and anti-inflammatory properties and therefore might be useful for the management of AD." | 2.82 | Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial. ( Chang, YS; Chen, CA; Chiang, BL; Chu, KH; Dai, YS; Lee, JH; Lee, PL; Lin, MH; Lin, YT; Sun, C; Wan, KS; Wang, LC; Yang, YH; Yu, HH, 2016) |
| "Atopic dermatitis is a chronic, pruritic inflammatory disease that often disrupts sleep in severely affected children, but there are limited studies to guide clinical management of these sleep problems." | 2.58 | Managing sleep disturbances in children with atopic dermatitis. ( Levoska, M; Patel, D; Shwayder, T, 2018) |
| "Oral melatonin supplement has been shown to improve dermatitis severity in children with AD, but the mechanism of the effect is unclear, and it is uncertain whether melatonin has a direct immunomodulatory effect on the dermatitis." | 1.72 | Topical Melatonin Exerts Immunomodulatory Effect and Improves Dermatitis Severity in a Mouse Model of Atopic Dermatitis. ( Chang, YS; Chiang, BL; Tang, CY; Tsai, CC; Yang, PY, 2022) |
| "Melatonin has pleiotropic properties such as suppressive effects on serum level of autotaxin which relieves itching of atopic dermatitis." | 1.48 | Is melatonin effective for pruritus caused by liver disease? ( Esmaeili, A; Namazi, S, 2018) |
| "Atopic dermatitis (AD), also known as atopic eczema, is chronic pruritic skin disease." | 1.46 | Melatonin inhibits neuronal dysfunction-associated with neuroinflammation by atopic psychological stress in NC/Nga atopic-like mouse models. ( Kim, YU; Lee, SH; Oh, DS; Park, G, 2017) |
| "Melatonin is a hormone secreted from the pineal gland and is a potent antioxidant." | 1.43 | Evaluation of Oxidant-Antioxidant Balance in Children with Atopic Dermatitis: A Case-Control Study. ( Abas, Bİ; Avcil, S; Uysal, P; Yenisey, Ç, 2016) |
| "The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization." | 1.43 | Assessing the New and Emerging Treatments for Atopic Dermatitis. ( Eichenfield, LF; Friedlander, SF; Irvine, AD; Simpson, EL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YS | 4 |
| Tsai, CC | 1 |
| Yang, PY | 1 |
| Tang, CY | 1 |
| Chiang, BL | 4 |
| Bešlić, I | 1 |
| Lugović-Mihić, L | 1 |
| Vrtarić, A | 1 |
| Bešlić, A | 1 |
| Škrinjar, I | 1 |
| Hanžek, M | 1 |
| Crnković, D | 1 |
| Artuković, M | 1 |
| Park, G | 2 |
| Lee, SH | 1 |
| Oh, DS | 1 |
| Kim, YU | 2 |
| Patel, D | 1 |
| Levoska, M | 1 |
| Shwayder, T | 1 |
| Taghavi Ardakani, A | 1 |
| Farrehi, M | 1 |
| Sharif, MR | 1 |
| Ostadmohammadi, V | 1 |
| Mirhosseini, N | 1 |
| Kheirkhah, D | 1 |
| Moosavi, SGA | 1 |
| Behnejad, M | 1 |
| Reiter, RJ | 2 |
| Asemi, Z | 1 |
| Jung, YS | 1 |
| Park, MK | 1 |
| Yang, CH | 1 |
| Esmaeili, A | 1 |
| Namazi, S | 1 |
| Chou, YT | 1 |
| Lee, JH | 2 |
| Lee, PL | 2 |
| Dai, YS | 2 |
| Sun, C | 2 |
| Lin, YT | 2 |
| Wang, LC | 2 |
| Yu, HH | 2 |
| Yang, YH | 2 |
| Chen, CA | 2 |
| Wan, KS | 2 |
| Marseglia, L | 1 |
| D'Angelo, G | 1 |
| Manti, S | 1 |
| Salpietro, C | 1 |
| Arrigo, T | 1 |
| Barberi, I | 1 |
| Gitto, E | 1 |
| Lin, MH | 1 |
| Chu, KH | 1 |
| Uysal, P | 1 |
| Avcil, S | 1 |
| Abas, Bİ | 1 |
| Yenisey, Ç | 1 |
| Eichenfield, LF | 1 |
| Friedlander, SF | 1 |
| Simpson, EL | 1 |
| Irvine, AD | 1 |
| Kim, TH | 1 |
| Jung, JA | 1 |
| Kim, GD | 1 |
| Jang, AH | 1 |
| Ahn, HJ | 1 |
| Park, YS | 1 |
| Park, CS | 1 |
| Kelsay, K | 1 |
| Kimata, H | 1 |
| Muñoz-Hoyos, A | 1 |
| Espín-Quirantes, C | 1 |
| Molina-Carballo, A | 1 |
| Uberos, J | 1 |
| Contreras-Chova, F | 1 |
| Narbona-López, E | 1 |
| Gutiérrez-Salmerón, MJ | 1 |
| Schwarz, W | 1 |
| Birau, N | 1 |
| Hornstein, OP | 1 |
| Heubeck, B | 1 |
| Schönberger, A | 1 |
| Meyer, C | 1 |
| Gottschalk, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| Effectiveness of Melatonin Supplement in the Management of Sleep Disturbances in Children With Atopic Dermatitis[NCT01638234] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
5 reviews available for melatonin and Dermatitis, Atopic
| Article | Year |
|---|---|
Melatonin in Dermatologic Allergic Diseases and Other Skin Conditions: Current Trends and Reports.
Topics: Alopecia Areata; Antioxidants; Dermatitis, Atopic; Humans; Melatonin; Skin | 2023 |
Managing sleep disturbances in children with atopic dermatitis.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Benzodiazepines; Child; Cognitive Behavioral Thera | 2018 |
Melatonin and atopy: role in atopic dermatitis and asthma.
Topics: Asthma; Dermatitis, Atopic; Humans; Immunoglobulin E; Immunomodulation; Interleukin-4; Melatonin | 2014 |
Mechanism of Sleep Disturbance in Children with Atopic Dermatitis and the Role of the Circadian Rhythm and Melatonin.
Topics: Child; Circadian Rhythm; Cytokines; Dermatitis, Atopic; Humans; Lymphocytes; Melatonin; Sleep Wake D | 2016 |
Management of sleep disturbance associated with atopic dermatitis.
Topics: Algorithms; Clonidine; Dermatitis, Atopic; Doxepin; Histamine H1 Antagonists; Humans; Hypnotics and | 2006 |
3 trials available for melatonin and Dermatitis, Atopic
| Article | Year |
|---|---|
The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial.
Topics: Child; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Immunoglobulin E; Iran; Male; Melato | 2018 |
Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Central Nervous System Depressants; Child; Child, Preschool; Cross-Over Stud | 2016 |
Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Central Nervous System Depressants; Child; Child, Preschool; Cross-Over Stud | 2016 |
Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Central Nervous System Depressants; Child; Child, Preschool; Cross-Over Stud | 2016 |
Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Central Nervous System Depressants; Child; Child, Preschool; Cross-Over Stud | 2016 |
Elevation of salivary melatonin levels by viewing a humorous film in patients with atopic eczema.
Topics: Adolescent; Amylases; Dermatitis, Atopic; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interfe | 2007 |
10 other studies available for melatonin and Dermatitis, Atopic
| Article | Year |
|---|---|
Topical Melatonin Exerts Immunomodulatory Effect and Improves Dermatitis Severity in a Mouse Model of Atopic Dermatitis.
Topics: Administration, Topical; Animals; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Model | 2022 |
Melatonin inhibits neuronal dysfunction-associated with neuroinflammation by atopic psychological stress in NC/Nga atopic-like mouse models.
Topics: Animals; Dermatitis, Atopic; Disease Models, Animal; Male; Melatonin; Mice; Neurons; Neurosecretory | 2017 |
Melatonin inhibits attention-deficit/hyperactivity disorder caused by atopic dermatitis-induced psychological stress in an NC/Nga atopic-like mouse model.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Cell Line, Transformed; Dermatitis, A | 2018 |
Is melatonin effective for pruritus caused by liver disease?
Topics: Animals; Cholestasis; Dermatitis, Atopic; Humans; Liver Diseases; Lysophospholipids; Melatonin; Mice | 2018 |
Atopic dermatitis, melatonin, and sleep disturbance.
Topics: Actigraphy; Child; Child, Preschool; Comorbidity; Cross-Sectional Studies; Cytokines; Dermatitis, At | 2014 |
Evaluation of Oxidant-Antioxidant Balance in Children with Atopic Dermatitis: A Case-Control Study.
Topics: Adolescent; Antioxidants; Case-Control Studies; Child; Child, Preschool; Dermatitis, Atopic; Female; | 2016 |
Assessing the New and Emerging Treatments for Atopic Dermatitis.
Topics: Child; Dermatitis, Atopic; Dietary Supplements; Humans; Interleukin-4 Receptor alpha Subunit; Interl | 2016 |
Melatonin inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Topics: Animals; Antioxidants; Dermatitis, Atopic; Dinitrofluorobenzene; Male; Melatonin; Mice; Skin Disease | 2009 |
Neuroendocrine and circadian aspects (melatonin and beta-endorphin) of atopic dermatitis in the child.
Topics: Adolescent; Adult; Aged; beta-Endorphin; Child; Child, Preschool; Circadian Rhythm; Dermatitis, Atop | 2007 |
Alterations of melatonin secretion in atopic eczema.
Topics: Adolescent; Adult; Circadian Rhythm; Dermatitis, Atopic; Female; Humans; Male; Melatonin; Pineal Gla | 1988 |